Organization
GRAIL, LLC, a subsidiary of Illumina, Inc.
12 abstracts
Abstract
Large-scale observational prospective cohort study of a multi-cancer early detection (MCED) test in symptomatic patients referred for cancer investigation.Org: Swansea Bay University Health Board, Oxford University Hospitals NHS Foundation Trust, GRAIL LLC, Department of Oncology, University of Oxford, University of Oxford,
Abstract
Methylated DNA biomarkers and incident cancer in the American Cancer Society (ACS) Cancer Prevention Study-3 (CPS-3) cohort.Org: GRAIL, LLC, a subsidiary of Illumina, Inc., Independent Statistical Consultant, UCL Hospitals, American Cancer Society, Illumina, Inc.,
Abstract
Diagnostic test use and time to cancer diagnosis in Medicare recipients.Org: GRAIL, LLC, a subsidiary of Illumina, Inc., Medicus Economics, LLC, Cleveland Clinic Lerner College of Medicine,
Abstract
Multi-cancer early detection (MCED) test performance in cancer survivors.Org: Dana-Farber Cancer Institute, GRAIL, LLC, a subsidiary of Illumina, Inc.,
Abstract
Impact of cancer screening results on patient-reported outcomes (PRO) and behavioral intentions.Org: Evidera, Inc, GRAIL, LLC, a subsidiary of Illumina, Inc., Ontada, Mayo Clinic, Dana-Farber Cancer Institute,
Abstract
Clinical evaluation of cancer signal origin prediction and diagnostic resolution following multi-cancer early detection testing.Org: GRAIL, LLC, a subsidiary of Illumina, Inc., Illumina, Inc., Sutter Health, Intermountain Healthcare, Mayo Clinic,
Abstract
Preclinical circulating tumor DNA (ctDNA) shedding duration and prognostic implications of modeling 3669 participants from American Cancer Society Cancer Prevention Study-3 (CPS-3) and Circulating Cell-free Genome Atlas substudy 3 (CCGA3).Org: American Cancer Society, GRAIL, LLC, a subsidiary of Illumina, Inc., Illumina, Inc., The Francis Crick Institute, University College London Cancer Institute,
Abstract
Methylation-based prediction of myelodysplastic syndrome survival outcomes.Org: GRAIL, LLC, a subsidiary of Illumina, Inc., Illumina, Inc., Columbia University - Mailman School of Public Health, Columbia University Medical Center,
Abstract
Early real-world (RW) experience with a multi-cancer early detection (MCED) test.Org: Adventist Health System/Sunbelt, Inc. d/b/a Advent Health Orlando, Fountain Life, MDVIP Medical Clinic of Houston, Signature Healthcare, PLLC, UnityPoint Clinic MDVIP,
Abstract
Examining the potential for lead-time bias by estimating stage-specific proportions of deaths due to diagnosed cancer.Org: GRAIL, LLC, a subsidiary of Illumina, Inc., Illumina, Inc., Menlo Park, CA, Washington University School of Medicine in St Louis, St. Louis, MO,
Abstract
Overall and non-lung cancer incidence in the National Lung Screening Trial (NLST) as indicators of potential for multi-cancer screening.Org: GRAIL, LLC, a subsidiary of Illumina, Inc., Illumina, Inc., Menlo Park, CA, University College London Cancer Institute, London, United Kingdom,
Abstract
Prevalence of cancer-related risk factors and associated cancer burden: A targeted literature review.Org: Cincinnati Cancer Advisors, GRAIL, LLC, a subsidiary of Illumina, Inc., Illumina, Inc.,